Rejoyn: How Otsuka Is Transforming Depression Care with Digital Therapy
MedTech Spotlight Live | Digital Therapeutics for Depression with Sarah Small
At the LSX World Congress in Boston, the MedTech Spotlight Live videocast by Orthogonal explored how digital therapeutics are reshaping mental health care. Sarah Small, Director of Health Experience and Applied Evidence at Otsuka Precision Health, joined Orthogonal’s Randy Horton to discuss Rejoyn, Otsuka’s FDA-cleared prescription digital therapeutic for major depressive disorder.
🔹 Key Insights from the Interview:
– Rejoyn combines CBT exercises and emotional face memory tasks to strengthen neural pathways and reduce depression symptoms.
– Otsuka’s “total healthcare” approach connects sickness and wellness to help people live fuller lives.
– Real-world evidence is essential to demonstrate Rejoyn’s clinical and economic impact.
– Adoption and reimbursement remain key challenges, clinician education and payer clarity will drive access.
– Success in digital therapeutics depends on creative implementation and seamless integration into clinical workflows.
As digital therapeutics mature, innovators like Otsuka Precision Health are showing how software can become medicine.
📌 Subscribe for more conversations with MedTech leaders.
#MedTech #DigitalTherapeutics #DepressionTreatment #MentalHealth #OtsukaPrecisionHealth #Rejoyn #LSXWorldCongress #SaMD #HealthcareInnovation
Timestamps:
00:00 Introduction
00:28 Meet Sarah Small from Otsuka Precision Health
01:15 Defining “Total Healthcare” and the Health Experience
02:05 Inside Rejoyn: How Digital Therapeutics Work
03:42 From Clinical Trials to Real-World Evidence
05:11 Overcoming Adoption and Reimbursement Barriers
06:22 The Future of Digital Mental Health Treatments